SG Americas Securities LLC Acquires 403,116 Shares of Orchard Therapeutics plc (NASDAQ:ORTX)

SG Americas Securities LLC grew its holdings in Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating) by 62.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,052,786 shares of the company’s stock after acquiring an additional 403,116 shares during the period. SG Americas Securities LLC owned 0.84% of Orchard Therapeutics worth $750,000 as of its most recent SEC filing.

Separately, Acadian Asset Management LLC bought a new position in Orchard Therapeutics in the fourth quarter worth approximately $141,000. Hedge funds and other institutional investors own 56.47% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Barclays reduced their price objective on shares of Orchard Therapeutics from $6.00 to $4.00 in a research note on Friday, May 13th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $7.75.

Orchard Therapeutics Stock Performance

Shares of NASDAQ ORTX opened at $0.52 on Tuesday. The firm has a fifty day moving average price of $0.56 and a 200-day moving average price of $0.71. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.06 and a quick ratio of 5.06. The stock has a market cap of $65.84 million, a PE ratio of -0.43 and a beta of 0.81. Orchard Therapeutics plc has a 1 year low of $0.41 and a 1 year high of $3.18.

Orchard Therapeutics (NASDAQ:ORTX – Get Rating) last posted its earnings results on Thursday, May 12th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.10). The company had revenue of $5.52 million for the quarter, compared to the consensus estimate of $4.97 million. Equities analysts anticipate that Orchard Therapeutics plc will post -0.95 earnings per share for the current fiscal year.

About Orchard Therapeutics

(Get Rating)

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration.

Read More

• Get a free copy of the StockNews.com research report on Orchard Therapeutics (ORTX)
• MarketBeat Podcast: Find Investing Opportunities For The Rest of 2022
• The Colgate-Palmolive Growth Outlook Brightens 
• Deep Value High Yield Newell Brands Is Ready To Bottom 
• These Stocks Outperformed Last Time There Was A Recession
• Does Rivian’s Stock Still Have A Future?

Want to see what other hedge funds are holding ORTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating).

Want More Great Investing Ideas?